3D Organoid Platform for Translational Modeling of Castration-Resistant Prostate Cancer
This technology is a 3D organoid model that mimics castration-resistant prostate cancer by combining three human cell types to study tumor-stromal interactions, hormone signaling, and drug resistance, enabling more accurate testing of cancer therapies in a human-like environment.
The Problem
Current preclinical models for studying CRPC, such as traditional two-dimensional cell cultures and animal models, fall short in replicating the human tumor microenvironment and the dynamic crosstalk between tumor and stromal cells. These systems often fail to capture the heterogeneity of tumor cell populations, the role of intracrine steroid hormone synthesis, and the impact of exosome-mediated signaling pathways that contribute to therapy resistance. Furthermore, animal models may not accurately reflect human-specific mechanisms, and conventional organoid models typically lack the integration of multiple relevant cell types and stromal components. As a result, these limitations impede the ability to study resistance mechanisms in a physiologically relevant context and hinder the discovery and testing of novel therapeutic agents that could target the complex biology of CRPC.
The Solution
This technology is a tri-cellular 3D organoid model specifically designed to study castration-resistant prostate cancer (CRPC) in a human-relevant setting. The system integrates three key human-derived cell types: androgen receptor (AR)-null CRPC cells, AR-positive hormone-sensitive CRPC cells, and patient-derived tumor-tropic adipose stem cells (ttpASCs), all co-cultured within a tissue matrix scaffold under hormone-deprived conditions.
The Opportunity
This setup closely mimics the clinical environment of androgen deprivation therapy, enabling the recreation of the intracrine testosterone-estradiol signaling axis and exosome-mediated communication between tumor and stromal cells. The AR-null cells synthesize testosterone to sustain AR-positive cells and release exosomes containing CYP19A1, which reprogram the ttpASCs to produce estradiol. This estradiol, in turn, supports the AR-null population, establishing a closed-loop system that mirrors the complex interactions driving therapy resistance in CRPC. The platform allows for detailed mechanistic studies and drug screening, including the evaluation of androgen receptor and aromatase inhibitors.
